Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Medical Device

ROBO Medical’s Innovative Gastrointestinal Endoscopic Instrument Gains NMPA Approval

Fineline Cube Mar 17, 2025

China’s National Medical Products Administration (NMPA) has approved ROBO Medical’s gastrointestinal endoscopic surgical instrument control...

Company Deals Drug

Basilea Pharmaceutica Marks Milestone as Cresemba Sales Soar in Asia Pacific

Fineline Cube Mar 17, 2025

Switzerland-based Basilea Pharmaceutica Ltd (SWX: BSLN) announced that its antifungal Cresemba (isavuconazole), commercialized by Pfizer...

Company

Phenomenex Inaugurates China R&D Center to Advance Danaher’s “Launching China” Strategy

Fineline Cube Mar 17, 2025

California-based Phenomenex, a leading manufacturer of chromatography consumables, announced the inauguration of its R&D center...

Company Drug

BMS’s Breyanzi Approved by EC for Relapsed or Refractory Follicular Lymphoma

Fineline Cube Mar 17, 2025

US giant Bristol-Myers Squibb (BMS; NYSE: BMY) announced receiving another indication approval from the European...

Company Deals

Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline

Fineline Cube Mar 17, 2025

Accropeutics Inc., a clinical-stage biotech company with operations in New York, US, and Suzhou, China,...

Company Drug

Life Molecular Imaging Launches Neuraceq in Hong Kong for Alzheimer’s Detection

Fineline Cube Mar 17, 2025

Life Molecular Imaging Ltd., a subsidiary of South Africa’s Life Healthcare Group focused on PET...

Company Drug

Frontera Therapeutics Receives NMPA Approval for FT-003 in Diabetic Retinopathy Study

Fineline Cube Mar 17, 2025

Sino-US firm Frontera Therapeutics, Inc. announced receiving approval from China’s National Medical Products Administration (NMPA)...

Company Medical Device

Inari Medical Wins NMPA Approval for Thrombectomy Stent System in China

Fineline Cube Mar 17, 2025

US-based Inari Medical, Inc. (NASDAQ: NARI), set to be acquired by Stryker (NYSE: SYK), announced...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ Tegileridine Approved for Postoperative Pain Management

Fineline Cube Mar 17, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving another indication approval from the...

Company Drug

Doma Biopharmaceutical’s HER3-MUC1 Targeted ADC DM002 Receives NMPA Clinical Approval

Fineline Cube Mar 17, 2025

China-based Doma Biopharmaceutical (Suzhou) Co., Ltd announced receiving clinical approval from the National Medical Products...

Company Medical Device

MicroPort Endovascular MedTech’s Cratos System Approved for Aortic Dissection Treatment

Fineline Cube Mar 17, 2025

Shanghai MicroPort Endovascular MedTech Co., Ltd’s (SHA: 688016) Cratos branched aortic stent graft system has...

Company Drug

Akeso Biopharma’s Penpulimab Approved for First-Line NPC Treatment

Fineline Cube Mar 17, 2025

China-based Akeso Biopharma (HKG: 9926) announced receiving another indication approval from the National Medical Products...

Company Drug

Innovent Biologics’ Sycume Approved by China’s NMPA for Thyroid Eye Disease

Fineline Cube Mar 17, 2025

China-based Innovent Biologics Inc. (HKG: 1801) announced that its New Drug Application (NDA) for Sycume...

Company Drug

Simcere Pharmaceutical’s ADC189 NDA Accepted for Influenza Treatment

Fineline Cube Mar 17, 2025

Simcere Pharmaceutical Group Limited (HKG: 2096) and AnDiConBio announced that the New Drug Application (NDA)...

Company

Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies

Fineline Cube Mar 16, 2025

Shanghai-based Rona Therapeutics announced the successful completion of a $25 million (RMB 180 million) Pre-B...

Company

Tonghua Golden-Horse Pharmaceutical Embraces AI with DeepSeek R1 for Drug Innovation

Fineline Cube Mar 16, 2025

Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (SHE: 000766) recently held a special meeting to deploy...

Digital

DeepSeek’s Rise in the Pharmaceutical Industry: A New Era of AI-Driven Transformation

Fineline Cube Mar 15, 2025

The emergence of DeepSeek-R1 during the Lunar New Year celebrations marked a pivotal moment in...

Company Deals

Pharmavan and Kefeng Changjian Sign Pact to Accelerate SPT-07A Development

Fineline Cube Mar 15, 2025

Suzhou Pharmavan Co., Ltd. has announced plans to enter into a cooperation agreement with Sichuan...

Company Drug

Roche’s Itovebi Approved in China for PIK3CA-Mutated Breast Cancer

Fineline Cube Mar 14, 2025

Itovebi (inavolisib), a best-in-class PI3Kα inhibitor from Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY), has...

Company Deals

Quantum Hi-Tech and ECNU Establish AI-Driven Drug Manufacturing Lab

Fineline Cube Mar 14, 2025

CRO+CDMO Quantum Hi-Tech (China) Biotechnology Co., Ltd (ChemPartner, SHE: 300149) announced plans to establish an...

Posts pagination

1 … 219 220 221 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.